Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

892
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
892
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

203
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
203
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs.

Clinical pharmacology and therapeutics·2026
Same author

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development.

Biologics : targets & therapy·2026
Same author

Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation.

Molecular pharmaceutics·2025
Same author

Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies.

Biologics : targets & therapy·2025
Same author

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Enzymatic Routes for Chiral Amine Synthesis: Protein Engineering and Process Optimization.

Biologics : targets & therapy·2024
Same journal

Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.

Biologics : targets & therapy·2026
Same journal

Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.

Biologics : targets & therapy·2026
Same journal

MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2.

Biologics : targets & therapy·2026
Same journal

Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.

Biologics : targets & therapy·2026
Same journal

Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.

Biologics : targets & therapy·2026
Same journal

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Biologics : targets & therapy·2026
See all related articles

Related Experiment Video

Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Evaluating Biosimilar Development Projects: An Analytical Framework Utilizing Net Present Value.

Ranjit Ranbhor1, Priyanka Kulkarni2

  • 1Pergament and Cepeda LLC, Florham Park, NJ, 07932, USA.

Biologics : Targets & Therapy
|April 1, 2025
PubMed
Summary
This summary is machine-generated.

Biosimilar development requires significant investment. A risk-adjusted Net Present Value (NPV) framework shows that achieving $250-300 million in peak sales is crucial for financial viability, driven by market share and manufacturing efficiency.

Keywords:
biosimilarsinvestment evaluationnet present value analysispharmaceutical developmentrisk assessment

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.7K

Related Experiment Videos

Last Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.7K

Area of Science:

  • Pharmaceutical economics
  • Biotechnology
  • Healthcare management

Background:

  • Biosimilars demand robust financial evaluation due to high investment ($100-250M) and long development timelines (6-8 years).
  • Traditional generic drug evaluation methods are insufficient for biosimilar development.

Purpose of the Study:

  • To present a comprehensive Net Present Value (NPV) analysis framework tailored for biosimilar development.
  • To incorporate technical, regulatory, and commercial factors into a risk-adjusted NPV methodology.

Main Methods:

  • Development of a risk-adjusted Net Present Value (NPV) framework.
  • Validation of the framework using case studies of three monoclonal antibody biosimilar development programs.

Main Results:

  • Successful biosimilar projects require minimum peak sales of $250-300 million for a positive NPV.
  • Market share and manufacturing efficiency are critical value drivers.
  • Clinical development constitutes the largest portion (57%) of total development costs.

Conclusions:

  • Early market entry, manufacturing optimization, and market share are key success factors for biosimilar development.
  • Technical complexity and competitive intensity significantly impact risk-adjusted returns.